| Q37064737 | A pharmacologic perspective on newly emerging T-cell manipulation technologies |
| Q36832129 | Bevacizumab in the treatment of non-small-cell lung cancer |
| Q34480735 | Catalytic in vivo protein knockdown by small-molecule PROTACs. |
| Q37723328 | Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents |
| Q39128248 | Determinants of the recommended phase 2 dose of molecular targeted agents |
| Q38198948 | Determining the optimal dose in the development of anticancer agents |
| Q60912743 | Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase |
| Q37198192 | Dose escalation methods in phase I cancer clinical trials |
| Q51819134 | Envisioning the future of early anticancer drug development. |
| Q35914787 | Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection |
| Q41276800 | Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors |
| Q64146996 | Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation |
| Q34545841 | Induced protein degradation: an emerging drug discovery paradigm |
| Q96635052 | PK/PD mediated dose optimization of emactuzumab, a CSF1R inhibitor, in patients with advanced solid tumors and diffuse-type tenosynovial giant cell tumor |
| Q92758119 | PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future |
| Q40629352 | Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. |
| Q99565924 | Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets |
| Q39396984 | Targeted Protein Degradation: from Chemical Biology to Drug Discovery |
| Q39367115 | Targeted protein knockdown using small molecule degraders |
| Q36905620 | Targeting developmental pathways in children with cancer: what price success? |
| Q52579980 | Targeting the protein kinase C family: are we there yet? |
| Q42573450 | The emerging low-dose therapy for advanced cancers |
| Q51689988 | The inverted pyramid of biomarker-driven trials. |
| Q36138272 | The motivations and methodology for high-throughput PET imaging of small animals in cancer research |
| Q37602380 | Translational research in phase I trials |
| Q90940964 | Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle |